Viewing Study NCT01662258


Ignite Creation Date: 2025-12-25 @ 12:08 AM
Ignite Modification Date: 2025-12-31 @ 8:19 PM
Study NCT ID: NCT01662258
Status: WITHDRAWN
Last Update Posted: 2016-04-19
First Post: 2012-08-03
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Microbiology Testing With the Aim Of Directed Antimicrobial Therapy For CAP
Sponsor: University of Pittsburgh
Organization:

Study Overview

Official Title: Microbiology Testing With the Aim Of Directed Antimicrobial Therapy For Community-Acquired Pneumonia
Status: WITHDRAWN
Status Verified Date: 2016-04
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Decision by NIH
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: NIHCAP
Brief Summary: This is a prospective interventional study to assess laboratory testing which will identify the microbial cause of pneumonia. This, in turn, will allow targeted antimicrobial agent selection for patients with community acquired-pneumonia (CAP).

Hypothesis: 1) To determine if Targeted strategy is non-inferior to Empiric therapy with respect to outcome endpoints. 2) To assess the use of innovative POC tests allows targeted narrow-spectrum antimicrobial therapy. 3) To determine if Targeted strategy is superior to Empiric therapy in patients with viral pneumonia
Detailed Description: The study will be conducted at five academic medical university sites with 7 hospitals. Empiric therapy is defined as selection of antibiotic therapy based on the 2007 ATS-IDSA guidelines in which broad-spectrum antibiotics are recommended, and microbial cause is uncertain

Study Oversight

Has Oversight DMC: True
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: